News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
88,423 Results
Type
Article (4690)
Company Profile (20)
Press Release (83713)
Section
Business (31080)
Career Advice (67)
Deals (6133)
Drug Delivery (17)
Drug Development (9276)
Employer Resources (10)
FDA (2137)
Job Trends (2927)
News (47810)
Policy (3788)
Tag
Academia (482)
Alliances (10508)
ALS (22)
Alzheimer's disease (387)
Antibody-drug conjugate (ADC) (26)
Approvals (2114)
Artificial intelligence (65)
Best Places to Work (2652)
Breast cancer (37)
Cancer (325)
Career advice (56)
CAR-T (25)
Cell therapy (78)
Clinical research (7286)
Collaboration (205)
COVID-19 (420)
C-suite (31)
Cystic fibrosis (21)
Data (226)
Diagnostics (1234)
Drug discovery (30)
Duchenne muscular dystrophy (23)
Earnings (10398)
Events (8890)
Executive appointments (90)
FDA (2291)
Funding (177)
Gene therapy (68)
GLP-1 (76)
Government (733)
Healthcare (2782)
Infectious disease (439)
IPO (2358)
Job creations (379)
Job search strategy (46)
Layoffs (59)
Legal (258)
Lung cancer (48)
Lymphoma (36)
Manufacturing (58)
Medical device (2030)
Medtech (2033)
Mergers & acquisitions (3867)
Metabolic disorders (58)
Neuroscience (464)
NextGen Class of 2024 (874)
Non-profit (1036)
Northern California (334)
Obesity (31)
Opinion (45)
Parkinson's disease (24)
People (8230)
Phase I (2215)
Phase II (3171)
Phase III (2860)
Pipeline (139)
Postmarket research (151)
Preclinical (760)
Press Release (32)
Radiopharmaceuticals (58)
Rare diseases (67)
Real estate (885)
Regulatory (3087)
Research institute (602)
Series A (30)
Series B (24)
Southern California (229)
Startups (850)
United States (2711)
Vaccines (87)
Date
Today (27)
Last 7 days (175)
Last 30 days (635)
Last 365 days (7067)
2024 (6864)
2023 (7622)
2022 (9286)
2021 (10569)
2020 (9379)
2019 (7511)
2018 (5268)
2017 (4680)
2016 (4081)
2015 (4176)
2014 (2601)
2013 (2034)
2012 (2274)
2011 (2323)
2010 (1876)
Location
Africa (77)
Asia (5987)
Australia (732)
California (680)
Canada (247)
China (65)
Colorado (26)
Connecticut (36)
Delaware (29)
Europe (13197)
Florida (85)
Illinois (69)
Indiana (47)
Japan (24)
Maryland (114)
Massachusetts (540)
Michigan (46)
Minnesota (35)
New Hampshire (23)
New Jersey (166)
New York (253)
North Carolina (140)
Northern California (334)
Ohio (44)
Pennsylvania (155)
South America (109)
Southern California (229)
Texas (68)
Utah (21)
Washington State (54)
88,423 Results for "advamed accel".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
BridgeBio Pharma, Inc. today announced sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
June 4, 2024
·
10 min read
Press Releases
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
October 8, 2024
·
5 min read
Business
Baylis Medical’s Kris Shah appointed to AdvaMed Accel Board of Directors
Baylis Medical Company has announced that President and co-Founder Kris Shah has been named to the Advanced Medical Technology Association’s (AdvaMed) Accel Board of Directors.
October 25, 2017
·
1 min read
Biotech Bay
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
Global Blood Therapeutics, Inc. has awarded approximately $450,000 to U.S. community-based organizations and institutions as part of the company’s 2021 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program.
June 15, 2021
·
10 min read
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified Huntington’s Disease Rating Scale, and neurofilament light chain levels to support the accelerated approval of its gene therapy AMT-130.
December 10, 2024
·
2 min read
·
Tristan Manalac
Editorial
FDA’s Accelerated Approval Pathway Drives Momentum for Intractable, Fatal Diseases
Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track record of propelling R&D for some of medicine’s most challenging illnesses.
December 2, 2024
·
6 min read
·
Heather McKenzie
Deals
Accel Clinical Services expands through acquisition, becomes Southeast clinical research powerhouse
Accel Clinical Services (ACS), the parent company of Accel Research Sites, is excited to announce its acquisition of the assets of AMPLIFY Clinical.
June 29, 2020
·
4 min read
Clinical Research Investments becomes Accel Clinical Services
Matt Maxwell, CEO of Accel Clinical Services, announced that Clinical Research Investments has officially become Accel Clinical Services (ACS), effective immediately. Maxwell explained the new name
March 10, 2020
·
2 min read
Press Releases
PhotoniCare Announces a First Close of $4.6 Million in Series B Financing, a Manufacturing Partnership with Gentex Corporation, and Relocation of its Headquarters to Grand Rapids, Michigan
December 4, 2024
·
5 min read
FDA
Evolving FDA Accelerated Approval Pathway Suffers Spate of Withdrawals
As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining concerned about confirmatory trials and clinical efficacy, especially as products greenlit under this pathway are pulled from the market.
October 28, 2024
·
7 min read
·
Heather McKenzie
1 of 8,843
Next
